Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark H Moss

Showing results (1-10 of 16) with videos related to

Pageof 2
Sort By:
Immunology and Allergy Clinics of North America|May 10, 2005
Immunotherapy: first do no harmMark H Moss
The Journal of Pediatrics|October 20, 2010
Children at risk for food-related anaphylaxis should carry two doses of epinephrineAlex Thomas, Mark H Moss
Cureus|January 6, 2026
Combined Posterior Tibial Tendon Transfer and Forefoot Reconstruction for Foot Drop and Forefoot Pain Secondary to Charcot-Marie-Tooth Disease: A Case Report and Literature ReviewMark H Moss, Angela M Garcia
Allergy and Asthma Proceedings|September 4, 2013
Retrospective analysis of the efficacy of omalizumab in chronic refractory urticariaRavi K Viswanathan, Mark H Moss, Sameer K Mathur
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|April 10, 2022
A 2-week medical student curriculum in an outpatient allergy clinicDaniel L Rosenberg, Mark H Moss, Sarah K Johnson, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|December 6, 2019
Real-world dosing of omalizumab for chronic spontaneous urticariaAmanda P McIntyre, Ravi K Viswanathan, Mark H Moss, et al.
Allergy and Asthma Proceedings|August 12, 2016
Safety and efficacy of beclomethasone dipropionate delivered by breath-actuated or metered-dose inhaler for persistent asthmaNiran J Amar, Mark H Moss, Edward M Kerwin, et al.
The Journal of Allergy and Clinical Immunology|January 3, 2006
Omalizumab pretreatment decreases acute reactions after rush immunotherapy for ragweed-induced seasonal allergic rhinitisThomas B Casale, William W Busse, Joel N Kline, et al.
Chest|March 6, 2022
Results of a Phase 2b Trial With GB001, a Prostaglandin D<sub>2</sub> Receptor 2 Antagonist, in Moderate to Severe Eosinophilic AsthmaMark H Moss, Njira L Lugogo, Mario Castro, et al.
Journal of Asthma and Allergy|August 25, 2021
Short-Term Subcutaneous Allergy Immunotherapy and Dupilumab are Well Tolerated in Allergic Rhinitis: A Randomized TrialJonathan Corren, Sarbjit S Saini, Remi Gagnon, et al.
Pageof 2

Showing results (1-10 of 16) with videos related to

Sort By:
Pageof 2
Immunology and Allergy Clinics of North America|May 10, 2005
Immunotherapy: first do no harmMark H Moss
The Journal of Pediatrics|October 20, 2010
Children at risk for food-related anaphylaxis should carry two doses of epinephrineAlex Thomas, Mark H Moss
Cureus|January 6, 2026
Combined Posterior Tibial Tendon Transfer and Forefoot Reconstruction for Foot Drop and Forefoot Pain Secondary to Charcot-Marie-Tooth Disease: A Case Report and Literature ReviewMark H Moss, Angela M Garcia
Allergy and Asthma Proceedings|September 4, 2013
Retrospective analysis of the efficacy of omalizumab in chronic refractory urticariaRavi K Viswanathan, Mark H Moss, Sameer K Mathur
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|April 10, 2022
A 2-week medical student curriculum in an outpatient allergy clinicDaniel L Rosenberg, Mark H Moss, Sarah K Johnson, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|December 6, 2019
Real-world dosing of omalizumab for chronic spontaneous urticariaAmanda P McIntyre, Ravi K Viswanathan, Mark H Moss, et al.
Allergy and Asthma Proceedings|August 12, 2016
Safety and efficacy of beclomethasone dipropionate delivered by breath-actuated or metered-dose inhaler for persistent asthmaNiran J Amar, Mark H Moss, Edward M Kerwin, et al.
The Journal of Allergy and Clinical Immunology|January 3, 2006
Omalizumab pretreatment decreases acute reactions after rush immunotherapy for ragweed-induced seasonal allergic rhinitisThomas B Casale, William W Busse, Joel N Kline, et al.
Chest|March 6, 2022
Results of a Phase 2b Trial With GB001, a Prostaglandin D<sub>2</sub> Receptor 2 Antagonist, in Moderate to Severe Eosinophilic AsthmaMark H Moss, Njira L Lugogo, Mario Castro, et al.
Journal of Asthma and Allergy|August 25, 2021
Short-Term Subcutaneous Allergy Immunotherapy and Dupilumab are Well Tolerated in Allergic Rhinitis: A Randomized TrialJonathan Corren, Sarbjit S Saini, Remi Gagnon, et al.
Pageof 2